Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Identification of a Small Molecule That Enhances Ferroptosis via Inhibition of Ferroptosis Suppressor Protein 1
Hiromasa Yoshioka1, Tatsuro Kawamura2, Makoto Muroi1,2
1Chemical Biology Research Group, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Abstract:
Glutathione peroxidase 4 (GPX4) is an intracellular enzyme that oxidizes glutathione while reducing lipid peroxides and is a promising target for cancer therapy. To date, several GPX4 inhibitors have been reported to exhibit cytotoxicity against cancer cells. However, some cancer cells are less sensitive to the known GPX4 inhibitors. This study aimed to explore compounds showing synergistic effects with GPX4 inhibitors. We screened a chemical library and identified a compound named NPD4928, whose cytotoxicity was enhanced in the presence of a GPX4 inhibitor. Furthermore, we identified ferroptosis suppressor protein 1 as its target protein. The results indicate that NPD4928 enhanced the sensitivity of various cancer cells to GPX4 inhibitors, suggesting that the combination might have therapeutic potential via the induction of ferroptosis.
Insights
Researchers discovered NPD4928, a compound that enhances cancer cell sensitivity to glutathione peroxidase 4 (GPX4) inhibitors. This combination therapy shows potential for cancer treatment by inducing ferroptosis.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Glutathione peroxidase 4 (GPX4) is a key enzyme in reducing lipid peroxides, making it a significant target in cancer therapy.
- Existing GPX4 inhibitors show cytotoxicity, but some cancer cells exhibit resistance, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify compounds that exhibit synergistic effects with GPX4 inhibitors.
- To explore novel therapeutic approaches for overcoming resistance to GPX4-targeted cancer therapy.
Main Methods:
- Screening of a chemical library to identify compounds potentiating GPX4 inhibitor activity.
- Identification of the target protein for the identified compound, NPD4928.
- Evaluation of NPD4928's effect on cancer cell sensitivity to GPX4 inhibitors.
Main Results:
- NPD4928 was identified as a compound that enhances the cytotoxicity of GPX4 inhibitors in cancer cells.
- The target protein of NPD4928 was identified as ferroptosis suppressor protein 1.
- NPD4928 significantly increased the sensitivity of various cancer cells to GPX4 inhibitors.
Conclusions:
- The combination of NPD4928 and GPX4 inhibitors demonstrates therapeutic potential.
- This synergistic approach may induce ferroptosis, offering a new strategy for cancer treatment.
